Official Journal
of the European Union

EN
L series

2026/2572

20.11.2026

COMMISSION IMPLEMENTING DECISION (EU) 2026/2572

of 19 November 2026

postponing the expiry date of the approval of brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flocoumafen for use in biocidal products of product-type 14 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products ([1]), and in particular Article 14(5) thereof,

After consulting the Standing Committee on Biocidal Products,

Whereas:

(1) Brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flocoumafen are approved as active substances for use in biocidal products of product-type 14 (rodenticides) under Regulation (EU) No 528/2012 by Commission Implementing Regulations (EU) 2017/1381 ([2]), (EU) 2017/1380 ([3]), (EU) 2017/1377 ([4]), (EU) 2017/1378 ([5]), (EU) 2017/1379 ([6]), (EU) 2017/1382 ([7]) and (EU) 2017/1383 ([8]) ('the approvals'). The approvals were to expire on 30 June 2024.

(2) In accordance with Article 13(1) of Regulation (EU) No 528/2012, applications were submitted to the European Chemicals Agency for the renewal of the approvals of brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flocoumafen for use in biocidal products of product-type 14 (rodenticides) ('the applications'). The applications have been evaluated by the competent authorities of Denmark, Finland, France, The Netherlands, Norway and Spain as the evaluating competent authorities.

([1]) OJ L 167, 27.6.2012, p. 1, ELI: http://data.europa.eu/eli/reg/2012/528/oj.
([2]) Commission Implementing Regulation (EU) 2017/1381 of 25 July 2017 renewing the approval of brodifacoum as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 39, ELI: http://data.europa.eu/eli/reg_impl/2017/1381/oj).
([3]) Commission Implementing Regulation (EU) 2017/1380 of 25 July 2017 renewing the approval of bromadiolone as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 33, ELI: http://data.europa.eu/eli/reg_impl/2017/1380/oj).
([4]) Commission Implementing Regulation (EU) 2017/1377 of 25 July 2017 renewing the approval of chlorophacinone as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 15, ELI: http://data.europa.eu/eli/reg_impl/2017/1377/oj).
([5]) Commission Implementing Regulation (EU) 2017/1378 of 25 July 2017 renewing the approval of coumatetralyl as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 21, ELI: http://data.europa.eu/eli/reg_impl/2017/1378/oj).
([6]) Commission Implementing Regulation (EU) 2017/1379 of 25 July 2017 renewing the approval of difenacoum as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 27, ELI: http://data.europa.eu/eli/reg_impl/2017/1379/oj).
([7]) Commission Implementing Regulation (EU) 2017/1382 of 25 July 2017 renewing the approval of difethialone as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 45, ELI: http://data.europa.eu/eli/reg_impl/2017/1382/oj).
([8]) Commission Implementing Regulation (EU) 2017/1383 of 25 July 2017 renewing the approval of flocoumafen as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 51, ELI: http://data.europa.eu/eli/reg_impl/2017/1383/oj).

(3) The evaluating competent authorities informed the Commission ([9]) that they had decided, pursuant to Article 14(1) of Regulation (EU) No 528/2012, that full evaluations of the applications were necessary.

(4) Commission Implementing Decision (EU) 2024/734 ([10]) postponed the expiry date of the approval of brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flocoumafen for use in biocidal products of product-type 14 to 31 December 2026, in order to allow sufficient time for the examination of the applications.

(5) In accordance with Article 14(3) of Regulation (EU) No 528/2012, on 14 May 2025, the European Chemicals Agency adopted the opinions ([11]), ([12]), ([13]), ([14]), ([15]), ([16]), ([17]) formulated by its Biocidal Products Committee, having regard to the conclusions of the evaluating competent authorities and submitted them to the Commission.

(6) According to the opinions of the European Chemicals Agency, brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flocoumafen are classified in Regulation (EC) No 1272/2008 of the European Parliament and of the Council ([18]) as toxic for reproduction category 1A or 1B, and thus they meet the exclusion criterion set out in Article 5(1), point (c), of Regulation (EU) No 528/2012. The substances brodifacoum, bromadiolone, difenacoum, difethialone and flocoumafen also meet the criteria in Regulation (EC) No 1907/2006 of the European Parliament and of the Council ([19]) for being persistent, bioaccumulative and toxic, and thus they meet the exclusion criterion set out in of Article 5(1), point (e), of Regulation (EU) No 528/2012. The substances difethialone and flocoumafen also meet the criteria in Regulation (EC) No 1907/2006 for being very persistent and very bioaccumulative ('vPvB'), and thus they meet the exclusion criterion set out in of Article 5(1), point (e), of Regulation (EU) No 528/2012.

(7) Pursuant to Article 12(1) of Regulation (EU) No 528/2012, the approvals of brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flocoumafen, may only be renewed if the active substances still meet the conditions laid down in Article 4(1) and at least one of the conditions set out in Article 5(2), first subparagraph, of that Regulation.

([9]) The evaluating competent authority of Denmark informed the Commission on 9 November 2023 for coumatetralyl, of Finland on 27 March 2023 for difenacoum, of France on 25 May 2023 for bromadiolone, of the Netherlands on 23 October 2023 for brodifacoum and flocoumafen, of Norway on 1 November 2023 for difethialone, of Spain on 18 October 2023 for chlorophacinone.

([10]) Commission Implementing Decision (EU) 2024/734 of 27 February 2024 postponing the expiry date of the approval of brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flocoumafen for use in biocidal products of product-type 14 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2024/734, 29.2.2024, ELI: http://data.europa.eu/eli/dec_impl/2024/734/oj).

([11]) Biocidal Products Committee (BPC) opinion on the application for renewal of approval of the active substance: Brodifacoum, Product type: 14, ECHA/BPC/469/2025, adopted on 14 May 2025.

([12]) Biocidal Products Committee (BPC) opinion on the application for renewal of approval of the active substance: Bromadiolone, Product type: 14, ECHA/BPC/475/2025, adopted on 14 May 2025.

([13]) Biocidal Products Committee (BPC) opinion on the application for renewal of approval of the active substance: Chlorophacinone, Product type: 14, ECHA/BPC/472/2025, adopted on 14 May 2025.

([14]) Biocidal Products Committee (BPC) opinion on the application for renewal of approval of the active substance: Coumatetralyl, Product type: 14, ECHA/BPC/471/2025, adopted on 14 May 2025.

([15]) Biocidal Products Committee (BPC) opinion on the application for renewal of approval of the active substance: Difenacoum, Product type: 14, ECHA/BPC/474/2025, adopted on 14 May 2025.

([16]) Biocidal Products Committee (BPC) opinion on the application for renewal of approval of the active substance: Difethialone, Product type: 14, ECHA/BPC/473/2025, adopted on 14 May 2025.

([17]) Biocidal Products Committee (BPC) opinion on the application for renewal of approval of the active substance: Flocoumafen, Product type: 14, ECHA/BPC/470/2025, adopted on 14 May 2025.

([18]) Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (OJ L 353, 31.12.2008, p. 1, ELI: http://data.europa.eu/eli/reg/2008/1272/oj).

([19]) Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1, ELI: http://data.europa.eu/eli/reg/2006/1907/oj).

(8) Considering the time still needed for the Commission to complete its analysis and submit a proposal for a decision on the renewals of the approvals of the active substances to the Standing Committee on Biocidal Products, including discussions with the Member States representatives, it will not be possible to adopt decisions on the applications before the expiry of the current approvals.

(9) Consequently, for reasons beyond the control of the applicants, the approvals are likely to expire before a decision has been taken on their renewal. It is therefore appropriate to further postpone the expiry date of the approvals for a period of time sufficient to complete the examination of the applications.

(10) Taking into account the time needed for the Commission to decide whether to renew the approvals of these active substances for use in biocidal products of product-type 14, the expiry dates of those approvals should be postponed to 31 December 2027.

(11) After the postponement of the expiry date of the approvals, brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flocoumafen remain approved for use in biocidal products of product-type 14 subject to the conditions set out in the Annexes to their approvals,

HAS ADOPTED THIS DECISION:

Article 1

The expiry date of the approval of brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flocoumafen for use in biocidal products of product-type 14 set out in Implementing Regulations (EU) 2017/1381, (EU) 2017/1380, (EU) 2017/1377, (EU) 2017/1378, (EU) 2017/1379, (EU) 2017/1382 and (EU) 2017/1383, respectively, is postponed to 31 December 2027.

Article 2

This Decision shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

Done at Brussels, 19 November 2026.

For the Commission
The President
Ursula VON DER LEYEN